RxDoctor Payments Data

Tambetta Ojong, MD

Family Medicine · Kinston, NCNPI 1881041176

Payments from drug & device makers

$610in general payments, 2019–2025

Across 24 payments — averaging $25.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$209
  • Novo Nordisk$146
  • GSK$98
  • Amgen$55
  • Pfizer$46
  • Exact Sciences$27
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca4$209
Novo Nordisk3$146
GSK6$98
Amgen4$55
Pfizer3$46
Exact Sciences2$27
Sanofi Pasteur Inc.1$15
Merck1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$610 in reported general payments places this provider in the 60th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$772
Medicare patients
17
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol158$161,972
EliquisApixaban54$68,848
OzempicSemaglutide62$65,997
JanuviaSitagliptin Phosphate40$39,491
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$36,888
EntrestoSacubitril/Valsartan34$36,117
TrulicityDulaglutide29$33,147
RybelsusSemaglutide25$30,455
TradjentaLinagliptin31$29,245
JardianceEmpagliflozin27$19,686
VascepaIcosapent Ethyl46$18,047
SymbicortBudesonide/Formoterol Fumarate50$16,502
Breo ElliptaFluticasone/Vilanterol21$13,982
LinzessLinaclotide16$13,099
Tresiba Flextouch U-100Insulin Degludec13$6,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort, Brilinta$209$183,578220 claims
Novo NordiskOzempic, Rybelsus$146$96,45387 claims
PfizerEliquis$46$68,84854 claims
GSKTrelegy Ellipta, Breo Ellipta$98$50,87061 claims
MerckJanuvia$14$39,49140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Kinston

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →